NORTHAMPTON, MA / ACCESS Newswire / February 19, 2025 / Take a spin through the latest in Gilead's science and innovation in our new series, The Centrifuge Sessions. Today we sit down with D. Barry Crittenden, Executive Director of Clinical Development, to discuss how Gilead is helping make an impact for people living with primary biliary cholangitis (PBC), a rare autoimmune disease that affects the liver.
Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Originally published by Gilead Sciences
View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.
Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com
SOURCE: Gilead Sciences
View the original press release on ACCESS Newswire
